DOCSLIB.ORG

Poisoning & Drug Overdose

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Poisoning & Drug Overdose Close Window Contributors Editor Kent R. Olson, MD, FACEP, FACMT, FAACT Clinical Professor of Medicine, Pediatrics, and Pharmacy, University of California, San Francisco; Medical Director, California Poison Control System, San Francisco Division Associate Editors Ilene B. Anderson, PharmD Clinical Professor of Pharmacy, University of California, San Francisco; Senior Toxicology Management Specialist, California Poison Control System, San Francisco Division Neal L. Benowitz, MD Professor of Medicine and Chief, Division of Clinical Pharmacology and Toxicology, University of California, San Francisco; Associate Medical Director, California Poison Control System, San Francisco Division Paul D. Blanc, MD, MSPH Professor of Medicine and Chief, Division of Occupational and Environmental Medicine, University of California, San Francisco Richard F. Clark, MD, FACEP Professor of Medicine, University of California, San Diego; Director, Division of Medical Toxicology and Medical Director, California Poison Control System, San Diego Division Thomas E. Kearney, PharmD, ABAT Professor of Clinical Pharmacy, University of California, San Francisco; Managing Director, California Poison Control System, San Francisco Division John D. Osterloh, MD, MS Chief Medical Officer, Division of Laboratory Sciences National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia Contributors Timothy E. Albertson, MD, PhD Professor of Medicine, Medical Pharmacology and Toxicology, University of California Medical Center, Davis; Medical Director, California Poison Control System, Sacramento Division [email protected] Section II: Amphetamines; Barbiturates; Dextromethorphan; Opiates and Opioids Judith A. Alsop, PharmD, DABAT Associate Clinical Professor, School of Pharmacy, University of California, San Francisco; Clinical Professor of Medicine, School of Medicine, University of California, Davis [email protected] Section II: Plants; Section III: Metoclopramide; Ondansetron; Potassium Ilene B. Anderson, PharmD Clinical Professor, School of Pharmacy, University of California, San Francisco; Senior Toxicology Management Specialist, California Poison Control System, San Francisco Division [email protected] Section II: Botulism; Camphor and Other Essential Oils; Ethylene Glycol and Other Glycols; Lomotil and Other Antidiarrheals; Methanol; Warfarin and Related Rodenticides John Balmes, MD Professor, Department of Medicine, University of California, San Francisco; Chief, Division of Occupational and Environmental Medicine, San Francisco General Hospital [email protected] Section II: Asbestos; Formaldehyde; Gases, Irritant; Molds; Phosgene; Sulfur Dioxide Neal L. Benowitz, MD Professor of Medicine and Chief, Division of Clinical Pharmacology and Toxicology, University of California, San Francisco; Associate Medical Director, California Poison Control System, San Francisco Division [email protected] Section II: Anesthetics, Local; Antiarrhythmic Drugs; Antidepressants, General (Noncyclic); Antidepressants, Tricyclic; Beta-Adrenergic Blockers; Calcium Antagonists; Cardiac Glycosides; Chloroquine and Other Aminoquinolines; Cocaine; Ergot Derivatives; Lithium; Marijuana; Monoamine Oxidase Inhibitors; Nicotine; Nitrates and Nitrites; Nitroprusside; Phencyclidine (PCP) and Ketamine; Pseudoephedrine, Phenylephrine and Other Decongestants; Quinidine and Other Type IA Antiarrhythmic Drugs; Quinine; Vacor (PNU); Section III: Dopamine; Epinephrine; Norepinephrine David P. Betten Assistant Clinical Professor, Department of Emergency Medicine, College of Human Medicine, Michigan State University, East Lansing [email protected] Section II: Colchicine Kathleen Birnbaum, PharmD Toxicology Management Specialist, Department of Clinical Pharmacy, University of California, San Francisco [email protected] Section III: Insulin; Leucovorin Calcium Paul D. Blanc, MD, MSPH Professor of Medicine, and Chief, Division of Occupational and Environmental Medicine, University of California, San Francisco [email protected] Section II: Carbon Disulfide; Cyanide; Isocyanates; Manganese; Metal Fume Fever; Methemoglobinemia; Nitrogen Oxides; Section IV: Evaluation of the Patient with Occupational Chemical Exposure; The Toxic Hazards of Industrial and Occupational Chemicals Stephen C. Born, MD, MPH Associate Clinical Professor, Division of Occupational and Environmental Medicine, University of California, San Francisco [email protected] Section II: Dioxins, Ethylene Oxide Alan Buchwald, MD Consultant in Medical Toxicology and Medical Director, Occupational Health Center, Dominican Santa Cruz Hospital, Santa Cruz, California [email protected] Section II: Copper Cindy Burkardt Toxicology Management Specialist, California Poison Control System, San Francisco Division [email protected] Section III: DTPA; Thiosulfate, Sodium Chris Camilleri, DO Attending Physician, University of California Davis Medical Center, Sacramento. Section II: Benzene F. Lee Cantrell, PharmD Assistant Clinical Professor, School of Pharmacy, University of California, San Diego and San Francisco; Interim Director, California Poison Control System, San Diego Division [email protected] Section II: Thyroid Hormone; Section III: Cyproheptadine; Folic Acid; Inamrinone (formerly Amrinone) Terry Carlson, PharmD Toxicology Management Specialist, California Poison Control System, Fresno/Madera Division [email protected] Section III: Naloxone and Nalmefene Richard F. Clark, MD Professor of Medicine, University of California, San Diego; Director, Division of Medical Toxicology, University of California Medical Center, San Diego; Medical Director, California Poison Control System, San Diego Division [email protected] Section II: Hymenoptera; Lionfish and Other Scorpaenoidea; Scorpions; Snakebite; Section III: Antivenom, Crotalinae (Rattlesnake); Antivenom, Latrodectus Mactans (Black Widow Spider); Antivenom, Micrurus Fulvius (Coral Snake), and Exotic Antivenoms Matthew D. Cook Assistant Clinical Professor, Medical Toxicology Fellow, and Attending Physician, Department of Emergency Medicine, University of California Medical Center, San Diego [email protected] Section II: Phosphorus Delia A. Dempsey, MD, MS Assistant Adjunct Professor of Pediatrics, Medicine, and Clinical Pharmacy, University of California, San Francisco; Assistant Medical Director, California Poison Control System, San Francisco Division [email protected] Section I: Special Considerations in Pediatric Patients; Section II: Bromides; Methyl Bromide; Pentachlorophenol and Dinitrophenol Jo Ellen Dyer, PharmD Clinical Professor, Department of Pharmacy, University of California, San Francisco; Senior Toxicology Management Specialist, California Poison Control System, San Francisco Division [email protected] Section I: Special Considerations in the Evaluation of Drug-Facilitated Assault; Section II: Azide, Sodium; Gamma- Hydroxybutyrate (GHB) Andrew Erdman, MD Clinical Pharmacology Fellow, University of California, San Francisco [email protected] Section II: Isoniazid (INH) Gary W. Everson, PharmD Toxicology Management Specialist, California Poison Control System, Fresno/Madera Division [email protected] Section II: Phenol and Related Compounds; Section III: Mannitol Jeffrey Fay, PharmD Assistant Clinical Professor, Department of Pharmacy, University of California, San Francisco; Toxicology Management Specialist, California Poison Control System, Fresno/Madera Division [email protected] Section II: Vasodilators Thomas J. Ferguson, MD, PhD Associate Clinical Professor of Internal Medicine, University of California, Davis; Medical Director, Cowell Student Health Center, University of California, Davis [email protected] Section II: Chromium; Thallium Frederick Fung, MD, MS Clinical Professor of Occupational Medicine, University of California, Irvine; Medical Director, Occupational Medicine Department and Toxicology Services, Sharp Rees-Stealy Medical Group, San Diego, California [email protected] Section II: Carbon Tetrachloride and Chloroform Mark J. Galbo, MS Environmental Toxicologist, School of Pharmacy, University of California, San Francisco; Poison Information Specialist, California Poison Control System, San Francisco Division [email protected] Section II: Naphthalene and Paradichlorobenzene; Warfare Agents—Chemical Fabian Garza, PharmD School of Pharmacy, University of California, San Francisco; Toxicology Management Specialist, California Poison Control System, Fresno/Madera Division [email protected] Section III: Methylene Blue Richard J. Geller, MD, MPH Associate Clinical Professor of Emergency Medicine, University of California, San Francisco; Medical Director, California Poison Control System, Fresno/Madera Division Section II: Disulfiram; Paraquat and Diquat; Selenium; Section III: Atropine and Glycopyrrolate; Pralidoxime (2- PAM) & Other Oximes Robert L. Goldberg, MD, FACOEM Director, Occupational and Environmental Medicine Residency Program; Health Sciences Associate Clinical Professor of Medicine, Department of Medicine, University of California, San Francisco [email protected] Section II: Polychlorinated Biphenyls (PCBs) Colin S. Goto, MD Assistant Clinical Professor of Pediatrics, University of California, San Diego; Attending Physician, Division of Emergency Medicine, Children's Hospital and Health Center, San Diego, California [email protected] Section II: Hydrocarbons Christine A. Haller, MD Assistant Professor of Medicine
Load more

  1132
Copy Link
Recommended publications
  • Picrotoxin-Like Channel Blockers of GABAA Receptors
    COMMENTARY Picrotoxin-like channel blockers of GABAA receptors Richard W. Olsen* Department of Molecular and Medical Pharmacology, Geffen School of Medicine, University of California, Los Angeles, CA 90095-1735 icrotoxin (PTX) is the prototypic vous system. Instead of an acetylcholine antagonist of GABAA receptors (ACh) target, the cage convulsants are (GABARs), the primary media- noncompetitive GABAR antagonists act- tors of inhibitory neurotransmis- ing at the PTX site: they inhibit GABAR Psion (rapid and tonic) in the nervous currents and synapses in mammalian neu- system. Picrotoxinin (Fig. 1A), the active rons and inhibit [3H]dihydropicrotoxinin ingredient in this plant convulsant, struc- binding to GABAR sites in brain mem- turally does not resemble GABA, a sim- branes (7, 9). A potent example, t-butyl ple, small amino acid, but it is a polycylic bicyclophosphorothionate, is a major re- compound with no nitrogen atom. The search tool used to assay GABARs by compound somehow prevents ion flow radio-ligand binding (10). through the chloride channel activated by This drug target appears to be the site GABA in the GABAR, a member of the of action of the experimental convulsant cys-loop, ligand-gated ion channel super- pentylenetetrazol (1, 4) and numerous family. Unlike the competitive GABAR polychlorinated hydrocarbon insecticides, antagonist bicuculline, PTX is clearly a including dieldrin, lindane, and fipronil, noncompetitive antagonist (NCA), acting compounds that have been applied in not at the GABA recognition site but per- huge amounts to the environment with haps within the ion channel. Thus PTX major agricultural economic impact (2). ͞ appears to be an excellent example of al- Some of the other potent toxicants insec- losteric modulation, which is extremely ticides were also radiolabeled and used to important in protein function in general characterize receptor action, allowing and especially for GABAR (1).
    [Show full text]
  • Current Awareness in Clinical Toxicology Editors: Damian Ballam Msc and Allister Vale MD
    Current Awareness in Clinical Toxicology Editors: Damian Ballam MSc and Allister Vale MD August 2016 CONTENTS General Toxicology 6 Metals 30 Management 14 Pesticides 31 Drugs 16 Chemical Warfare 33 Chemical Incidents & 24 Plants 34 Pollution Chemicals 25 Animals 34 CURRENT AWARENESS PAPERS OF THE MONTH Toxicity evaluation of α-pyrrolidinovalerophenone (α-PVP): results from intoxication cases within the STRIDA project Beck O, Franzén L, Bäckberg M, Signell P, Helander A. Clin Toxicol 2016; 54: 568-75. Context An increasing number of new psychoactive substances (NPS) of different chemical classes have become available through marketing and sale over the Internet. This report from the Swedish STRIDA project presents the prevalence, laboratory results, and clinical features in a series of intoxications involving the stimulant NPS -pyrrolidinovalerophenone (-PVP), a potent dopamine re-uptake inhibitor, over a 4-year period. Study design Observational case series of consecutive patients with admitted or suspected intake of NPS presenting to hospitals in Sweden from 2012 to 2015. Patients and methods In the STRIDA project, blood and urine samples are collected from intoxicated patients with admitted or suspected intake of NPS or unknown drugs presenting to hospitals over the country. Analysis of NPS is performed by mass spectrometry multicomponent methods. Clinical data are collected when caregivers consult the Swedish Poisons Information Centre Current Awareness in Clinical Toxicology is produced monthly for the American Academy of Clinical Toxicology by the Birmingham Unit of the UK National Poisons Information Service, with contributions from the Cardiff, Edinburgh, and Newcastle Units. The NPIS is commissioned by Public Health England 2 (PIC), and retrieved from medical records.
    [Show full text]
  • Toxicity Equivalence Factors for Marine Biotoxins Associated with Bivalve Molluscs TECHNICAL PAPER
    JOINT FAO/WHO Toxicity Equivalency Factors for Marine Biotoxins Associated with Bivalve Molluscs TECHNICAL PAPER Cover photograph: © FAOemergencies JOINT FAO/WHO Toxicity equivalence factors for marine biotoxins associated with bivalve molluscs TECHNICAL PAPER FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS WORLD HEALTH ORGANIZATION ROME, 2016 Recommended citation: FAO/WHO. 2016. Technical paper on Toxicity Equivalency Factors for Marine Biotoxins Associated with Bivalve Molluscs. Rome. 108 pp. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations (FAO) or of the World Health Organization (WHO) concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or products of manufacturers, whether or not these have been patented, does not imply that these are or have been endorsed or recommended by FAO or WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by FAO and WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall FAO and WHO be liable for damages arising from its use.
    [Show full text]
  • XXXV International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 26–29 May 2015, St Julian's, Malta
    Clinical Toxicology ISSN: 1556-3650 (Print) 1556-9519 (Online) Journal homepage: http://www.tandfonline.com/loi/ictx20 XXXV International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 26–29 May 2015, St Julian's, Malta To cite this article: (2015) XXXV International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 26–29 May 2015, St Julian's, Malta, Clinical Toxicology, 53:4, 233-403, DOI: 10.3109/15563650.2015.1024953 To link to this article: http://dx.doi.org/10.3109/15563650.2015.1024953 Published online: 26 Mar 2015. Submit your article to this journal Article views: 3422 View related articles View Crossmark data Citing articles: 2 View citing articles Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ictx20 Download by: [UPSTATE Medical University Health Sciences Library] Date: 28 December 2016, At: 10:31 Clinical Toxicology (2015), 53, 233–403 Copyright © 2015 Informa Healthcare USA, Inc. ISSN: 1556-3650 print / 1556-9519 online DOI: 10.3109/15563650.2015.1024953 ABSTRACTS XXXV International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 26–29 May 2015, St Julian ’ s, Malta 1. Modelling dose-concentration-response Introduction: The American Association of Poison Control Cen- ters (AAPCC) published its fi rst annual report in 1983. Call data Ursula Gundert-Remy from sixteen US poison centers was chronicled in that report. Seven submitted data for the entire year. By July 2000, 63 centers Institute for Clinical Pharmacology and Toxicology, Charit é were part of the national poison center system, but only 59 submit- Medical School, Berlin, Germany ted data for the full year.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.204,630 B2 Shirley Et Al
    USOO920463OB2 (12) United States Patent (10) Patent No.: US 9.204,630 B2 Shirley et al. (45) Date of Patent: Dec. 8, 2015 (54) CAPSULE FORMULATION (58) Field of Classification Search CPC ... A01N 2300/00: A01N 43/90: A01N 47/02: (75) Inventors: Ian Malcolm Shirley, Bracknell (GB); A01N 25/22: A01N 25/28 Tanya Wright, Basel (CH); Robert See application file for complete search history. Michael Perrin, Bracknell (GB); Patrick Mulqueen, Bracknell (GB); Anne Waller, Bracknell (GB); Andy (56) References Cited Pierce, Bracknell (GB) U.S. PATENT DOCUMENTS (73) Assignee: Syngenta Participations AG, Basel 4,440,756 A * 4/1984 Herve et al. ................... 514,521 (CH) 6,395,776 B1* 5/2002 Losel et al. ................... 514,531 2002/003730.6 A1* 3/2002 Van Koppenhagen et al. ............................. 424/408 (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 2004/O198704 A1* 10, 2004 Shuster et al. ... 514/151 U.S.C. 154(b) by 1634 days. 2004/0235898 A1* 11/2004 Klein et al. ................... 514,318 (21) Appl. No.: 11/817,068 FOREIGN PATENT DOCUMENTS CN 1386419 A 12/2002 (22) PCT Filed: Feb. 23, 2006 CN 149 1552 A 4/2004 DE 4009 141 A1 9, 1990 (86). PCT No.: PCT/EP2006/OO1657 DE 19503157 A1 8, 1995 EP O761096 A 3, 1997 S371 (c)(1), WO 89,04170 A 5, 1989 (2), (4) Date: Aug. 19, 2008 WO OO/O5951. A 2, 2000 (87) PCT Pub. No.: WO2006/089747 OTHER PUBLICATIONS PCT Pub. Date: Aug. 31, 2006 Anonymous, “Pyrethrinoids Stabilized by Non-azo—dyes'.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/00284.18 A1 Parker Et Al
    US 2011 002841 8A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/00284.18 A1 Parker et al. (43) Pub. Date: Feb. 3, 2011 (54) USE OF GABBA RECEPTOR ANTAGONISTS Publication Classification FOR THE TREATMENT OF EXCESSIVE SLEEPINESS AND DISORDERS ASSOCATED (51) Int. Cl. WITH EXCESSIVE SLEEPINESS A63L/7028 (2006.01) A 6LX 3/557 (2006.01) (75) Inventors: Kathy P. Parker, Rochester, NY A63L/335 (2006.01) (US); David B. Rye, Dunwoody, A63L/4355 (2006.01) GA (US); Andrew Jenkins, A63L/047 (2006.01) Decatur, GA (US) A6IP 25/00 (2006.01) Correspondence Address: (52) U.S. Cl. ........... 514/29: 514/220; 514/450, 514/291; FISH & RICHARDSON P.C. (AT) 5147738 P.O BOX 1022 Minneapolis, MN 55440-1022 (US) (57) ABSTRACT (73) Assignee: Emory University, Atlanta, GA GABA receptor mediated hypersomnia can be treated by (US) administering a GABA receptor antagonist (e.g., flumazenil; clarithromycin; picrotoxin; bicuculline; cicutoxin; and (21) Appl. No.: 12/922,044 oenanthotoxin). In some embodiments, the GABA receptor antagonist is flumazenil or clarithromycin. The GABA (22) PCT Filed: Mar. 12, 2009 receptor mediated hypersomnia includes shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, narco (86). PCT No.: PCT/USO9/37034 lepsy, excessive sleepiness, hypersomnia (e.g., idiopathic hypersomnia; recurrent hyperSonmia; endozepine related S371 (c)(1), recurrent stupor; and amphetamine resistant hyperSonmia), (2), (4) Date: Sep. 10, 2010 and excessive sleepiness associated with shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, and Related U.S. Application Data hypersomnia (e.g., idiopathic hypersomnia; recurrent hyper (60) Provisional application No.
    [Show full text]
  • Environmental Science Water Research & Technology
    Environmental Science Water Research & Technology View Article Online CRITICAL REVIEW View Journal | View Issue Hydrophilic trace organic contaminants in urban Cite this: Environ. Sci.: Water Res. stormwater: occurrence, toxicological relevance, Technol., 2020, 6,15 and the need to enhance green stormwater infrastructure Stephanie Spahr, †*ab Marc Teixidó, bc David L. Sedlak bc and Richard G. Luthy *ab Hydrophilic trace organic contaminants (hyphil-TrOCs) are polar, often ionizable organic compounds of anthropogenic origin that have various applications in the urban environment e.g., as pesticides, plasticizers, and flame retardants. Hyphil-TrOCs can be washed off in storm events and enter surface waters via untreated urban stormwater discharges or combined sewer overflows. Though trace concentrations of these chemicals may pose a risk to ecosystem and human health, information on their Creative Commons Attribution 3.0 Unported Licence. presence in urban stormwater remains elusive. Monitoring and source apportionment of hyphil-TrOCs in urban stormwater is complicated by the vast number and sources of organic contaminants and the high variability in aqueous concentration over time and space. Here, we present the current state of knowledge on the occurrence and toxicological relevance of hyphil-TrOCs in urban stormwater. To mitigate negative impacts of contaminated surface runoff to receiving water bodies and to prevent sanitary or combined sewer overflows, many cities implement sustainable green stormwater infrastructure, also called best
    [Show full text]
  • Meeting Materials)
    California State Board of Pharmacy BUSINESS, CONSUMER SERVICES AND HOUSING AGENCY 1625 N. Market Blvd, N219, Sacramento, CA 95834 DEPARTMENT OF CONSUMER AFFAIRS Phone: (916) 574-7900 GOVERNOR EDMUND G. BROWN JR. Fax: (916) 574-8618 www.pharmacy.ca.gov ENFORCEMENT AND COMPOUNDING COMMITTEE REPORT April 18, 2017 Amy Gutierrez, PharmD, Licensee Member, Chair Allen Schaad, Licensee Member, Vice Chair Greg Lippe, Public Member Stan Weisser, Licensee Member Valerie Muñoz, Public Member Ricardo Sanchez, Public Member I. Call to Order, Establishment of Quorum, and General Announcements II. Public Comments on Items Not on the Agenda/Agenda Items for Future Meetings Note: The board may not discuss or take action on any matter raised during this public comment section that is not included on this agenda, except to decide whether to place the matter on the agenda of a future meeting. [Government Code sections 11125, 11125.7(a)] III. Enforcement Matters a. University of California, San Diego’s Pilot Program to Permit Patients to Access Medications from an Automated Drug Delivery System Not Immediately Adjacent to the Pharmacy Background At the April 2015 Board Meeting, the board approved an 18-month pilot study under the auspices of the University of California, San Diego (UCSD) School of Pharmacy involving use of an automated drug delivery system (ADDS) for prescription medication from which staff of Sharp Hospital in San Diego and their families, who opted in, could pick up their outpatient medications. Consultation would be provided via telephone before medication could be dispensed to a patient for first time fills. Since that time the committee has received quarterly updates on the study, including usage of the system.
    [Show full text]
  • 1-Iodo-1-Pentyne
    MIAMI UNIVERSITY-THE GRADUATE SCHOOL CERTIFICATE FOR APPROVING THE DISSERTATION We hereby approve the Dissertation of Lizhi Zhu Candidate for the Degree: Doctor of Philosophy ________________________________ Robert E. Minto, Director ________________________________ John R. Grunwell, Reader ________________________________ John F. Sebastian, Reader ________________________________ Ann E. Hagerman, Reader ________________________________ Richard E. Lee, Graduate School Representative ABSTRACT INVESTIGATING THE BIOSYNTHESIS OF POLYACETYLENES: SYNTHESIS OF DEUTERATED LINOLEIC ACIDS & MECHANISM STUDIES OF DMDS ADDITION TO 1,4-ENYNES By Lizhi Zhu A wide range of polyacetylenic natural products possess antimicrobial, antitumor, and insecticidal properties. The biosyntheses of these natural products are widely distributed among fungi, algae, marine sponges, and higher plants. As details of the biosyntheses of these intriguing compounds remains scarce, it remains important to develop molecular probes and analytical methods to study polyacetylene secondary metabolism. An effective pathway to prepare selectively deuterium-labeled linoleic acids was developed. By this Pd-catalyzed method, deuterium can be easily introduced into the vinyl position providing deuterolinoleates with very high isotopic purity. This method also provides a general route for the construction of 1,4-diene derivatives with different chain lengths and 1,4-diene locations. Linoleic acid derivatives (12-d, 13-d and 16,16,17,17,18,18,18-d7) were synthesized according to this method. A stereoselective synthesis of methyl (14Z)- and (14E)-dehydrocrepenynate was achieved in five to six steps that employed Pd-catalyzed cross-coupling reactions to construct the double bonds between C14 and C15. Compared with earlier methods, the improved syntheses are more convenient (no spinning band distillations or GLC separation of diastereomers were necessary) and higher Z/E ratios were obtained.
    [Show full text]
  • Fall TNP Herbals.Pptx
    8/18/14 Introduc?on to Objecves Herbal Medicine ● Discuss history and role of psychedelic herbs Part II: Psychedelics, in medicine and illness. Legal Highs, and ● List herbs used as emerging legal and illicit Herbal Poisons drugs of abuse. ● Associate main plant and fungal families with Jason Schoneman RN, MS, AGCNS-BC representave poisonous compounds. The University of Texas at Aus?n ● Discuss clinical management of main toxic Schultes et al., 1992 compounds. Psychedelics Sacraments: spiritual tools or sacred medicine by non-Western cultures vs. Dangerous drugs of abuse vs. Research and clinical tools for mental and physical http://waynesword.palomar.edu/ww0703.htm disorders History History ● Shamanic divinaon ○ S;mulus for spirituality/religion http://orderofthesacredspiral.blogspot.com/2012/06/t- mckenna-on-psilocybin.html http://www.cosmicelk.net/Chukchidirections.htm 1 8/18/14 History History http://www.10zenmonkeys.com/2007/01/10/hallucinogenic- weapons-the-other-chemical-warfare/ http://rebloggy.com/post/love-music-hippie-psychedelic- woodstock http://fineartamerica.com/featured/misterio-profundo-pablo- amaringo.html History ● Psychotherapy ○ 20th century: un;l 1971 ● Recreaonal ○ S;mulus of U.S. cultural revolu;on http://qsciences.digi-info-broker.com http://www.uspharmacist.com/content/d/feature/c/38031/ http://en.wikipedia.org/nervous_system 2 8/18/14 Main Groups Main Groups Tryptamines LSD, Psilocybin, DMT, Ibogaine Other Ayahuasca, Fly agaric Phenethylamines MDMA, Mescaline, Myristicin Pseudo-hallucinogen Cannabis Dissociative
    [Show full text]
  • Author Index Page Numbers in Italics Refer to Bibliography
    Author Index Page Numbers in italics refer to bibliography Aaron,T.H., Criep,L.H. 180. Adams,M.R., see Litchfield,J. Albert,A., Serjeant,E.P. 176, 207 T., Jr. 386, 409, 432, 441, 207 Aaron, T. H., see Criep, L. H. 465,496 Albert,J.R., see Lish,P.M. 398,427 Adamson,D.W., Barrett,P.A., 449, 465, 466, 495 Aarsen,P.N., Zeegers,A. 15, Billinghurst, J. W., Green, A. Albert, U., see Giertz, H. 444, 30 F .. Jones,T.S.G. 190,192, 489 Abbozzo, G., Genazzani, E., 207 Alberty,J. 387,425, 442, Donatelli, L. 562,570 Adamson, D. W., Barrett, P. A., 452--455,480 Abdel-Galil, A. A. M., Marshall, Billinghurst,J. W., Jones, T. Alberty, J., Huurrekorpi, L. P. B. 114, 122 S.G. 190,207 399, 425, 455, 480 Aborg, e.-H .. Novotny,J., Adamson, D. W., Billinghurst, Alberty,J., Schiede,M. 399, Uvniis,B. 86.90 J.W. 189,194,207 425,455,480 Aborg,e. H., Uvniis,B. 87, 90 Adashek, D., Grossman, M. I. Alberty, J., Takkunen, R. 467, Aborg, C.-H., see Uvniis,B. 58. 46,47,55 480 74. 75, 82, 84-87. 92 Adlerova, E., see Protiva, M. Albinus,M., Sewing.K.F. 2, Abram, L. E., see Cohen, M. B. 201, 212 3, 6, 8, 11, 21, 30, 264, 287, 421,427 Ado,A.D., Abrossimow,W.N. 463,480 Abrams,G., see Lear,E. 566, 453.480 Albrecht, I., see Cort, J. H. 579, 571 Ado, A. D., Ishimova, L. M., 597 Abramson, D.
    [Show full text]
  • Is Palatability of a Root-Hemiparasitic Plant Influenced by Its Host Species?
    Oecologia (2005) 146: 227–233 DOI 10.1007/s00442-005-0192-3 PLANTANIMALINTERACTIONS Martin Scha¨dler Æ Mareike Roeder Æ Roland Brandl Diethart Matthies Is palatability of a root-hemiparasitic plant influenced by its host species? Received: 16 November 2004 / Accepted: 21 June 2005 / Published online: 19 July 2005 Ó Springer-Verlag 2005 Abstract Palatability of parasitic plants may be influ- Introduction enced by their host species, because the parasites take up nutrients and secondary compounds from the hosts. If Parasitic plants attack shoots or roots of other plants and parasitic plants acquired the full spectrum of secondary take up water, nutrients and solutes from the hosts by compounds from their host, one would expect a corre- means of specialized contact organs (haustoria, Kuijt lation between host and parasite palatability. We 1969). About 1% of all plants are parasitic and parasitic examined the palatability of leaves of the root-hemi- plants are common components of many plant commu- parasite Melampyrum arvense grown with different host nities (Molau 1995). The majority of parasitic plants are plants and the palatability of these host plants for two actually hemiparasites that have green leaves and are generalist herbivores, the caterpillar of Spodoptera lit- able to photosynthesize (Kuijt 1969). Parasitic plants can toralis and the slug Arion lusitanicus. We used 19 species drastically reduce the growth of their host plants and of host plants from 11 families that are known to con- some are important agricultural pests (Parker and Riches tain a wide spectrum of anti-herbivore compounds. 1993; Pennings and Callaway 2002). Because parasitic Growth of M.
    [Show full text]